PMID- 26424236
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20151001
LR  - 20200930
IS  - 1738-6586 (Print)
IS  - 2005-5013 (Electronic)
IS  - 1738-6586 (Linking)
VI  - 11
IP  - 4
DP  - 2015 Oct
TI  - Postthrombolytic Antiplatelet Use for Patients with Intercerebral Hemorrhage 
      without Extensive Parenchymal Involvement Does Not Worsen Outcome.
PG  - 305-10
LID - 10.3988/jcn.2015.11.4.305 [doi]
AB  - BACKGROUND AND PURPOSE: It is unclear whether postthrombolytic antiplatelet (AP) 
      therapy after thrombolytic-related hemorrhage without extensive parenchymal 
      involvement (THEPI) affects the clinical outcome. This study explored whether AP 
      administration in patients with THEPI affects short- and long-term outcomes. 
      METHODS: All of the data for this study were collected from the Thrombolysis 
      Implementation and Monitor of Acute Ischemic Stroke in China (TIMS-China) 
      registry. Patients with THEPI were assigned to either the AP (AP therapy should 
      be commenced 24 h after intravenous thrombolysis) or AP-naive groups. THEPI was 
      defined according to European-Australasian Acute Stroke Study II criteria. The 
      90-day functional outcome, 7-day National Institutes of Health Stroke Scale 
      (NIHSS) score, and 7-day and 90-day mortalities were compared between the AP and 
      AP-naive groups. Logistic regression analysis wy on the short- and long-term 
      clinical outcomes. RESULTS: Of the 928 patients enrolled from those in the 
      TIMS-China registry (n=1,440), 89 (9.6%) had nonsymptomatic intracerebral 
      hemorrhage (ICH) within 24-36 h after thrombolysis; 33 (37%) of these patients 
      were given AP therapy (AP group) and 56 (63%) were not (AP-naive group). No 
      significant differences were found for the risk of 7-day aggravated ICH 
      (p=0.998), 7-day NIHSS score (p=0.5491), 7-day mortality [odds ratio (OR)=3.427; 
      95% confidence interval (95% CI)=0.344-34.160; p=0.294], 90-day mortality 
      (OR=0.788, 95% CI=0.154-4.040, p=0.775), or modified Rankin score 5 or 6 at 
      90-days (OR=1.108, 95% CI=0.249-4.928, p=0.893) between the AP and AP-naive 
      groups after THEPI. CONCLUSIONS: Early administration of postthrombolytic AP 
      therapy after THEPI does not worsen either the short- or long-term outcome. AP 
      therapy may be a reasonable treatment option for patients with THEPI to reduce 
      the risk of ischemic stroke recurrence.
FAU - Jia, Weihua
AU  - Jia W
AD  - Department of Neurology, Beijing Tian Tan Hospital, Capital Medical University, 
      Beijing, China.
FAU - Zhou, Lichun
AU  - Zhou L
AD  - Department of Neurology, Beijing Chao-Yang Hospital, Capital Medical University, 
      Beijing, China.
FAU - Liao, Xiaoling
AU  - Liao X
AD  - Department of Neurology, Beijing Tian Tan Hospital, Capital Medical University, 
      Beijing, China.
FAU - Pan, Yuesong
AU  - Pan Y
AD  - Department of Neurology, Beijing Tian Tan Hospital, Capital Medical University, 
      Beijing, China.
FAU - Wang, Yongjun
AU  - Wang Y
AD  - Department of Neurology, Beijing Tian Tan Hospital, Capital Medical University, 
      Beijing, China. yongjunwang1962@gmail.com.
LA  - eng
PT  - Journal Article
PL  - Korea (South)
TA  - J Clin Neurol
JT  - Journal of clinical neurology (Seoul, Korea)
JID - 101252374
PMC - PMC4596115
OTO - NOTNLM
OT  - antiplatelet therapy
OT  - ischemic stroke
OT  - outcome
OT  - thrombolytic-related hemorrhage
COIS- Conflicts of Interest: The authors have no financial conflicts of interest.
EDAT- 2015/10/02 06:00
MHDA- 2015/10/02 06:01
PMCR- 2015/10/01
CRDT- 2015/10/02 06:00
PHST- 2014/06/11 00:00 [received]
PHST- 2014/10/01 00:00 [revised]
PHST- 2014/10/01 00:00 [accepted]
PHST- 2015/10/02 06:00 [entrez]
PHST- 2015/10/02 06:00 [pubmed]
PHST- 2015/10/02 06:01 [medline]
PHST- 2015/10/01 00:00 [pmc-release]
AID - 201510305 [pii]
AID - 10.3988/jcn.2015.11.4.305 [doi]
PST - ppublish
SO  - J Clin Neurol. 2015 Oct;11(4):305-10. doi: 10.3988/jcn.2015.11.4.305.